The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels.

The main questions it aims to answer are:

Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood?

Participants will:

Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers

Lipoprotein(a), or Lp(a), is a genetically determined cholesterol particle that increases the risk of heart disease and stroke. High levels of Lp(a) affect about 1 in 4 people, and there are no approved treatments that directly reduce its harmful effects. One reason Lp(a) is thought to be harmful is that it carries oxidized phospholipids, which promote inflammation and blood clotting.

2-hydroxybenzylamine (2-HOBA, also known as Hobamine) is a naturally occurring compound that neutralizes reactive molecules responsible for forming oxidized lipids. Preclinical studies and early human trials suggest that 2-HOBA is safe and may lower the buildup of oxidized phospholipids.

This pilot clinical trial will test whether oral 2-HOBA supplementation can improve the biology of Lp(a) in people with high levels (≥90 mg/dL). Ten adults will take 2-HOBA (400 mg by mouth, three times daily with meals) for 6 weeks. Blood and urine will be collected at three clinic visits (baseline, mid-study, and end of study). Researchers will measure oxidized phospholipids, lipoprotein function, markers of inflammation (such as C-reactive protein and interleukins), and markers of clotting (such as fibrinogen, D-dimer, and platelet activity).

The results will provide early information about whether 2-HOBA can reduce harmful changes linked to high Lp(a) and help guide the design of larger future trials.

Inclusion Criteria:

• Males and females aged 18-69 years.
• Elevated Lp(a) levels ≥ 90 mg/dL.
• Able to provide informed consent and adhere to study schedules.
• Willing to follow a physician-recommended diet during the study.

Exclusion Criteria:

• Pregnant, planning pregnancy during the study period, or currently breastfeeding.
• Individuals with established cardiovascular disease
• Planning major changes in diet or exercise routines.
• Experienced >20% weight change in the past 3 months.
• Diagnosed with malabsorption syndrome or chronic diarrhea.
• Abnormal liver, kidney, or thyroid function.
• Drug or alcohol abuse within the past 6 months, or significant mental/psychological impairment.
• Have known bleeding disorders (e.g., hemophilia).
• Planned surgery during the study period.
• Donated blood within the last 2 weeks or planning to donate during the study.
• Require regular blood transfusions.